Biology and treatment of acute promyelocytic leukemia

Current Opinion in Oncology

Volumn 8, Issue 1, 1996, Pages 3-12

  Fenaux, Pierre ^a   Chomienne, Christine ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; PREDNISOLONE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BLOOD CLOTTING DISORDER; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL DIFFERENTIATION; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; HUMAN; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOEMBOLISM;

EID: 0029938058     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199601000-00002     Document Type: Review

References (92)

1. Corey SJ, Locker J, Oliveri DR, Shekhter-Levin S, Redner RL, Penchansky L, Gollin SM: A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia 1994, 8(suppl 8):1350-1353.
2. Najfeld V, Chen A, Scalise A, Ambinder EP, Fernandez G, Waxman S: Myeloblastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. Genes Chromosom Cancer 1994, 10(suppl 1):15-25.
3. Borrow J, Shipley J, Howe K, Kiely F, Goddard A, Sherr D, Srivastava A, Antony AC, Fioretos T, Mitelman F: Molecular analysis of simple variant translocations in acute promyelocytic leukemia. Genes Chromosom Cancer 1994, 9(suppl 4):234-243.
4. Zelent A: Translocation of the RAR alpha locus to the PML or PLZF gene in acute promyelocytic leukemia. Br J Haematol 1994, 86(suppl 3):451-460.
5. Hatzis T, Satnden GR, Howell RT, Savill C, Wagstaft A, Scott GL: Acute promyelocytic leukemia (M3): relapse with acute myeloblastic leukemia (M2) and DIC (5:17)(q11;p11). Am J Haematol 1995, 48(suppl 1):40-44.
6. Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH: The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 1994, 8(suppl 7):1108-1112. An updated immunophenotypic analysis of 452 AML samples screened with 22 monoclonal antibodies.
7. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardo C, Del Vecchio L: Expression and ATRA-driven modulation of adhesion molecules in acute promyelocytic leukemia. Leukemia 1994, 26(suppl 1):29-37.
8. Erber WN, Asbahr H, Rule SA, Scott CS: Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD8 antibodies. Br J Haematol 1994, 88(suppl 1):101-104.
9. Pandolfi PP, Alcalay M, Fagioli M, Zangrili D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaub M-P, Chambon P, Pelicci PG: Genomic variability and alternative splicing generate multiple PML/RARA transcripts that encode aberrant PML proteins and PML/RARA isoforms in acute promyelocytic leukaemia. EMBO J 1992, 11:1397-1407.
10. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: Differentiation of acute promyelocytic cells by all-trans retinoic acid: II. In vitro studies: structure-function relationships. Blood 1990, 76:1710-1717.
11. Castaigne S, Balitrand N, De The H, DeJean A, Degos L, Chomienne C: A PML/RARa fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992, 79:3110.
12. Dombret H, Scrobohaci ML, Daniel MT, Miclea JM, Castaigne S, Chomienne C, Fenaux P, Degos L: In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995, 9:19-24. A description and modulation of blood coagulation disorders in APL patients before and during ATRA therapy. Though fibrinolysis is rapidly corrected, disseminated intravascular coagulation persists despite ATRA treatment.
13. Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, Degos L: Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment Leukemia 1993, 7:2-9.
14. Warrel RP, Frankel SR, Miller WH, Scheinberg DA, Itri IM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dimitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991, 324:1385.
15. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995, 85:1083-1094. The only review article on the t(11,17) cases of PLZF-RARα positive with in vivo and in vitro studies with retinoic acid.
16. Guidez F, Huang W, Tong JH, Dubois C, Balitrand N, Waxman S, Michaux JL, Martiat P, Degos L, Chen Z, Chomienne C: Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF-RARα patient Leukemia 1994, 8:312-317.
17. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, Degos L, Waxman S, Zelent A, Chomienne C: PLZF-RAR fusion protein generated from the translocation t(11;17)(q23;q21) displays altered transactivation properties against the wild-type retinoic acid receptors. Proc Natl Acad Sci U S A 1994, 91:1178-1182. Description of the PLZF gene and comparative dominant negative effect of PLZF-RAR and PML-RAR on the transcription of retinoic acid target genes.
18. Dubois C, Schlageter MH, De Gentile A, Guidez F, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L, Chomienne C: Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic leukemia. Blood 1994, 83:3264-3270.
19. Dubois C, Schlageter MH, de Gentile A, Guidez F, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L, Chomienne C: Modulation of IL-6 and IL-1b and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994, 8:1750-1757. Cytokine secretion by APL cells and modulation by retinoic acid may be relevant to retinoic acid efficacy and retinoic acid syndrome in vivo.
20. Matikainen S, Tapiovaara H, Vaheri A, Hurme M: Activation of IL-1 beta gene expression during retinoic acid-induced granulocytic differentiation of promyeloid leukemia cells. Cell Growth Differ 1994, 5(suppl 9):975-982.
21. Seale J, Delva L, Renesto P, Balitrand N, Dombret H, Scrobohaci M-L, Degos L, Paul P, Chomienne C: All-trans retinoic acid rapidly decreases Cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia 1996, in press.
22. de Gentile A, Toubert ME, Dubois C, Krawice I, Schlageter MH, Balitrand N, Castaigne S, Degos L, Rain JD, Najean Y, Chomienne C: Induction of high-affinity GM-CSF receptors during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1994, 8:1758-1762.
23. Glasser L, Fiederlein RL: Functional characteristics of in vivo induced neutrophils after differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid. Cancer 1994, 73(suppl 4):1206-1212.
24. Martin SJ, Bradley JG, Cotter TG: HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990, 79:448-453.
25. Tosi P, Visani G, Gibellini D, Zauli G, Ottoviani E, Cenacchi A, Gamberi B, Manfroi S, Marchisio M, Tura S: All-trans retinoic acid and induction of apoptosis in acute promyelocytic leukemia cells. Leuk Lymphoma 1994, 14(suppl 5-6):503-507.
26. Calabresse C, Barbey S, Venturini L, Balitrand N, Degos L, Fenaux P, Chomienne C: In vitro treatment with retinoids or the topoisomerase inhibitor, VP16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. Leukemia 1995, in press. APL cells have increased survival in liquid suspension culture. Retinoic acid does not induce apoptosis despite differentiation induction.
27. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti L, Pelicci PG: The acute promyelocytic leukemia-specific PML-RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74:423-431.
28. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute leukemia: I. Clinical results. Blood 1990, 76:1704-1709.
29. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci PG, Lo Coco F: Absence of reverse transcription-polymerase chain reaction detectable residual diseases in patients with acute promyelocytic leukemia in long-term remission. Blood 1993, 82(suppl 12):3556-3559.
30. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S: Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993, 82(suppl 4):1264-1269.
31. Diverio D, Pandolfi PP, Rossi V, Biondi A, Pelicci G, Lo Coco F: Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 1994, 8(suppl 7):1105-1107.
32. Fukutani H, Naoe T, Ohno R, Yoshida H, Kiyooi H, Miyawaki S, Morishita H, Sano F, Kmibayashi H, Matsue K: Prognostic significance of the RT-PCR assay of PML-RARα transcripts in acute promyelocytic leukemia: the Leukemia Study Group of the ministry of Health and Welfare (Kouseisho). Leukemia 1995, 9(suppl 4):588-593.
33. Castaigne S, Lefebvre P, Chomienne C, Suc E, Rigal-Huguet F, Gardin C, Delmer A, Archimbaud E, Tilly H, Janvier M, Isnard F, Travade P, Monfort L, Lannoy A, Rapp MJ, Christian B, Montastruc M, Weh H, Fenaux P, Dombret H, Gourmel B, Degos L: Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 1993, 82:3560-3563.
34. Delva L, Cornic M, Balitrand N, Guidez F, Miclea JM, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C: Resistance to all-trans retinoic acid therapy in relapsing acute promyelocytic leukemia. Blood 1993, 82:2175-2181.
35. Cornic M, Delva L, Castaigne S, Balitrand N, Degos L, Chomienne C: In vitro all-trans retinoic acid (ATRA sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994, 8(suppl 6):914-917. This paper, as well as that of Delva et al. (Blood 1993, 82:2175-2181), places retinoic acid increased catabolism as the cause of ATRA-induced secondary resistance in APL patients and showing CRABPII as a marker of this status.
36. Cornic M, Delva L, Castaigne S, Balitrand N, Degos L, Chomienne C: In vitro all-trans retinoic acid (ATRA sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994, 8(suppl 6):914-917. This paper, as well as that of Delva et al. (Blood 1993, 82:2175-2181), places retinoic acid increased catabolism as the cause of ATRA-induced secondary resistance in APL patients and showing CRABPII as a marker of this status.
37. Miller WH, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for PML-RARα fusion mRNA. Blood 1993, 82(suppl 6):1689-1694.
38. Tapiovaara H, Matikainen S, Hurme M, Vaheri A: Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently down regulated by production of inhibitors. Blood 1994, 83:1883-1891.
39. Lefebvre P, Thomas G, Gourmel B, Dreux C, Castaigne S, Chomienne C: Pharmacokinetics of all-trans RA in patients with acute promyelocytic leukemia. Leukemia 1991, 5:1054-1062.
40. Muindi J, Frankel SR, Huselton C, DeGrazia F, Garland WA, Yong CW, Warrell RP: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992, 52:2133-2140.
41. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dimitrovsky E: Continuous treatment with all-trans RA progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood 1992, 79:299-305.
42. Adamson PC: Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia. Semin Haematol 1994, 31(suppl 4):14-17.
43. Agadir A, Cornic C, Lefebvre P, Gourmel B, Balitrand N, Degos L, Chomienne C: Differential uptake of all-trans retinoic acid by acute promyelocytic leukemic cells: evidence for its role in retinoic acid efficacity. Leukemia 1995, 9:139-145. First analysis of intracellular concentration of retinoic acid in APL cells correlating maximal levels and retinoic acid differentiation.
44. Vyas RC, Frankel SR, Aghor P, Warrell RP, Hittleman WN: Probing the pathobiology of response to all-trans RA in acute promyelocytic leukemia: PCC/FISH analysis. Blood 1996, in press.
45. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet 1989, 1:748-755.
46. Gratas C, Menot ML, Dresch C, Chomienne C: Retinoic acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. Leukemia 1993, 7:1156-1162.
47. Van Bockstaele DR, Lenjou M, Snoeck HW, Lardon F, Stryckmans P, Peetermans ME: Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study of BM mononuclear cells and on isolated CD34+ BM cells. Ann Haematol 1993, 66:61-66.
48. Collins SJ, Roberton KA, Le Moyne Mueller: Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-a). Mol Cell Biol 1990, 10:2154-2163.
49. de The H, Lavau C, Marchio A, Chomienne C, Degos L, DeJean A: The PML/RARα fusion mRNA generated by the t(15;17) translocations in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:676-685.
50. Rousselot P, Hardas B, Castaigne S, DeJean A, de The H, Degos L, Farzaneh F, Chomienne C: The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid induced granulocytic differentiation. Oncogene 1994, 9:545-551. This paper, along with Grignani et al. (Cancer Res 1995, 55[suppl 2]:440-443) and Turhan et al. (Blood 1995, 85[suppl 8]:2154-2161), clearly demonstrates that the PML-RARα protein blocks ATRA-induced myeloid differentiation.
51. Rousselot P, Hardas B, Castaigne S, DeJean A, de The H, Degos L, Farzaneh F, Chomienne C: The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid induced granulocytic differentiation. Oncogene 1994, 9:545-551. This paper, along with Grignani et al. (Cancer Res 1995, 55[suppl 2]:440-443) and Turhan et al. (Blood 1995, 85[suppl 8]:2154-2161), clearly demonstrates that the PML-RARα protein blocks ATRA-induced myeloid differentiation.
52. Rousselot P, Hardas B, Castaigne S, DeJean A, de The H, Degos L, Farzaneh F, Chomienne C: The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid induced granulocytic differentiation. Oncogene 1994, 9:545-551. This paper, along with Grignani et al. (Cancer Res 1995, 55[suppl 2]:440-443) and Turhan et al. (Blood 1995, 85[suppl 8]:2154-2161), clearly demonstrates that the PML-RARα protein blocks ATRA-induced myeloid differentiation.
53. Koken MHM, Puvion Dutilleuil F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, De Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de The H: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994, 13:1073-1083. One of the leading articles demonstrating that the PML protein defines a specific nuclear structure, which is disrupted by the presence of PML-RARα and reverts to a normal configuration after RA differentiation.
54. Daniel MT, Koken M, Romagne O, Barbey S, Barzarbachi A, Stadler M, Guillemin MC, Degos L, Chomienne C, de The H: PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993, 82:1858-1867.
55. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A: Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. Embo J 1993, 12:1161-1167.
56. Grignani F, Testa U, Mascuilli R, Mariani G, Fagioli M, Barberi T, Peschle C, Pelicci PG: Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. Cancer Res 1995, 55(suppl 2):440-443.
57. Turhan AG, Lemoine FM, Debert C, Bonnet ML, Baillou C, Picard F, MacIntyre EA, Varet B: Highly purified primitive hematopoietic stem cells are PML-RARα negative and generate monoclonal progenitors in acute promyelocytic leukemia. Blood 1995, 95(suppl 8):2154-2161.
58. Head D, Kopecky KJ, Willman CL, Appelbaum FR: Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG) trial. Leukemia 1994, 8(suppl 2):S38-S41. Clonality analysis in two samples of patients with APL showed that the CD34+ CD38- fraction was PML-RARα negative.
59. Willemze R, Suciu S, Mandelli F, De Witte TH, Cadiou M, Castoldi GL, Liso V, Dardenne M, Solbu G, Zittoun R: Treatment of patients with acute promyelocytic leukemia: the EORTC-LCG experience. Leukemia 1994, 8(suppl 2):S48-S55.
60. Bassan R, Battista R, Viero P, D'Emilio A, Buelli M, Montaldi A, Rambaldi A, Tremul L, Dini E, Barbui T: Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 1995, 9:238-243.
61. Cunningham I, Gee T, Reich L: Acute promyelocytic leukemia: treatment results during a decade at Memorial hospital. Blood 1989, 73:1116.
62. Fenaux P, Pollet JP, Vandenbossche L, Dupriez B, Jouet JP, Bauters F: Treatment of acute promyelocytic leukemia: a report on 70 cases. Leuk Lymphoma 1991, 4:249.
63. Rodighiero F, Avvisati G, Castaman G, Mandelli F: Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 1990, 11:2112.
64. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Huebner G, Bauters F, Fegueux N, Fey M, Sanz M, Lowenberg B, Maloisel F, Auzanneau G, Sadoun A, Gardin C, Bastion Y, Ganser A, Jacky E, Dombret H, Chastang C, Degos L: Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993, 82:3241-3249.
65. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C, Castaigne S, Fenaux P: All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85:2643-2653. In this report, the authors updated the results of their randomized trial comparing chemotherapy alone and ATRA followed by chemotherapy in newly diagnosed APL. With a minimum follow-up of 21 months, the incidence of relapse remained significantly lower, and actuarial survival and event-free survival remained higher after ATRA followed by chemotherapy. They also updated results of an earlier pilot study of ATRA followed by chemotherapy, which after a minimum follow-up of 38 months still gave better results than chemotherapy alone.
66. Fenaux P, Wattel E, Archimbaud E, Sanz M, Hecquet B, Guerci A, Link H, Fegueux N, Fey M, Castaigne S, Degos L: Prolonged follow up confirms that all transretinoic acid (ATRA) followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (APL). Blood 1994, 84:666.
67. Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR: Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update in the New York experience. Leukemia 1994, 8:926. In this report, the authors confirmed (in a nonrandomized fashion) their better results obtained with ATRA followed by chemotherapy by comparison to chemotherapy alone.
68. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995, 85:1202-1206. In this report, the authors showed better results in newly diagnosed APL with a combination of ATRA and chemotherapy by comparison with a historical control treated with chemotherapy alone.
69. 3 or rapidly increase with ATRA, and that chemotherapy should be also added in those cases.
70. Awisati G, Baccarini M, Ferrara F, Lazzarino M, Resegotti L, Mandelli F: AIDA protocol (all-trans retinoic acid + idarubicin) in the treatment of newly diagnosed acute promyelocytic leukemia (APL): a pilot study of the Italian cooperative group GIMENA [abstract]. Blood 1994, 84:380a.
71. Seiter K, Miller WH, Feldman EJ, Ahmed T, Arlin Z: Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. Leukemia 1995, 9:15-18.
72. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsch-Ginsberg C, Stass S, Keating M, Estey E: All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994, 73:2946-2952.
73. Eardley AM, Heller G, Warrell RP: Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 1994, 8:934-939.
74. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell R: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992, 117:292.
75. Visani G, Tosi P, Cenacchi A, Manfroi S, Gamberi B, Ottaviani E, Tura S: Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia. Leuk Lymphoma 1994, 15:143-147.
76. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA, Warrell RP: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994, 84:3843-3849. The authors critically review the necessity of adding chemotherapy in order to prevent the ATRA syndrome in APL and conclude that chemotherapy is rarely required. They show that expression of CD13 on blasts, rather than leukocyte counts, can be a predicting factor of ATRA syndrome, and that patients with a PML-RAR breakpoint in bcr3 region may have a higher relapse risk.
77. Warrell RP: The "standard of care" in acute promyelocytic leukemia. Leukemia 1994, 8(suppl 2):S56-S58.
78. Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A, Sierra J, Meloni G, Frassoni F, Golman J, Gratwohl A, Gorin NC: European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Bone Marrow Transplant 1994, 14:293-303. The authors reviewed the outcome of allogeneic and autologous bone marrow transplantation in first or second complete response in APL, in patients who had received chemotherapy alone as a first-line therapy. It appears that these procedures, in first complete response are not superior to ATRA followed by chemotherapy except perhaps in some high-risk patients, but that they probably represent the only chance of achieving cure in second complete response.
79. Miller WH, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M, Warrel RP: 9-cis Retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995, 85:3021-3027.
80. Miller VA, Rigas JR, Muindi JRF, Tong WP, Venkatraman E, Kris MG, Warrel RP: Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1996, in press.
81. Jurcic JG, Caron PC, Miller WH, Yao TJ, Maskal P, Finn RD, Larson SM, Warrel RP, Scheinberg DA: Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995, 9:244-248.
82. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G: Liposome encapsulation circumvents the hepatic clearance mechanism of all-trans retinoic acid. Leuk Res 1994, 18:587-596.
83. Iwakiri R, Inokuchi K, dan K, Nomura T: Marked basophilia in acute promyelocytic leukemia treated with all-trans retinoic acid: molecular analysis of the cell origin of the basophils. Br J Haematol 1994, 86:870-872.
84. Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, Tsukada N, Takahashi H, Kimura H, Ueno M, Arakawa M, Shibata A: Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994, 8:1113-1115.
85. Tomas JF, Escudero A, Fernandez-Ranada JM: All-trans retinoic acid treatment and Sweet syndrome. Leukemia 1994, 8:1596-1598.
86. Miranda N, Oliveira P, Frade MJ, Melo J, Marques MS, Parreira A: Myositis with tretinoin. Lancet 1994, 344:1096.
87. Limentani SA, Pretell JO, Potter D, Dubois JS, Daoust PR, Spieler PS, Miller KB: Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Am J Hematol 1994, 47:50-55.
88. Dreosti LM, Bezwoda W, Gunter K: Bone marrow necrosis following all-trans retinoic acid therapy for acute promyelocytic leukemia. Leuk Lymphoma 1994, 13:353-356.
89. Stentoft J, Lanng Nielsen J, Hvidman LE: All-trans retinoic acid in acute promyelocytic leukemia in late pregnancy. Leukemia 1994, 8:1585-1588.
90. Celo JS, Kim HC, Houlihan C, Canavan BF, Manzullo GP, Saidi P: Acute promyelocytic leukemia in pregnancy: all-trans retinoic acid as a newer therapeutic option. Obstet Gynecol 1994, 83:808-811.
91. Weiss MA, Warrell RP: Two cases of extramedullary acute promyelocytic leukemia: cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer 1994, 74:1882-1886.
92. Thomas X, Fiere D, Archimbaud E: Persistence of retinoic acid sensitivity in relapsed acute promyelocytic leukemia with extramedullary involvement. Leukemia 1994, 8:520-521.